Abstract：
The discovery of new molecular biomarkers of cancer during the last decades and the development of new diagnostic devices exploiting those have significantly contributed to the clinical analysis of cancer and to improve the outcomes. Among those, liquid biopsy sensors exploiting aptamers for the detection of cancer biomarkers in body fluids are useful and accurate tools for a fast and inexpensive non-invasive screening of population. The incorporation of aptamers in electrochemical sandwich biosensors using enzyme labels, a so-called ELASA, has demonstrated its utility to improve the detection schemes. In this review, we overview the existing ELASA assays for numerous cancer biomarkers as alternatives to the traditional ELISA and discuss their possibilities to reach the market, currently dominated by optical immunoassays.
摘要：
在过去的几十年中，癌症的新分子生物标志物的发现以及利用这些标志物的新诊断设备的开发为癌症的临床分析和改善结果做出了重大贡献。其中,液体活检传感器利用适体来检测体液中的癌症生物标志物，对于快速且廉价的非侵入性人群筛查是有用且准确的工具。使用酶标记在电化学夹心生物传感器中掺入适体，所谓的ELASA,已经证明了它在改进检测方案方面的实用性。在这次审查中,我们概述了现有的许多癌症生物标志物的ELASA测定作为传统ELISA的替代品，并讨论了它们进入市场的可能性，目前以光学免疫测定为主。
